Breathlessness, phlegm and mortality: 26 Years of follow-up in healthy middle-aged Norwegian men

Journal of Internal Medicine

Volumn 260, Issue 4, 2006, Pages 332-342

  Stavem, K ^a   Sandvik, L ^b   Erikssen, J ^a  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cohort study; Dyspnoea; Fitness; Mortality; Phlegm; Respiratory symptoms

Indexed keywords

ADULT; ARTICLE; CHEMICAL ANALYSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; COUGHING; DYSPNEA; FITNESS; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; LUNG FUNCTION; MALE; MORTALITY; NORWAY; PHLEGMON; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SPIROMETRY; SYMPTOMATOLOGY;

ADULT; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COUGH; DYSPNEA; EXERCISE; HUMANS; MALE; MIDDLE AGED; NORWAY; OCCUPATIONAL DISEASES; PHYSICAL FITNESS; PROSPECTIVE STUDIES; RESPIRATION DISORDERS; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SMOKING;

EID: 33748574961     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2006.01693.x     Document Type: Article

References (60)

1. Higgins MW, Keller JB. Predictors of mortality in the adult population of Tecumseh. Arch Environ Health 1970; 21: 418-24.
2. Krzyzanowski M, Wysocki M. The relation of thirteen-year mortality to ventilatory impairment and other respiratory symptoms: the Cracow Study. Int J Epidemiol 1986; 15: 56-64.
3. Beaty TH, Cohen BH, Newill CA, Menkes HA, Diamond EL, Chen CJ. Impaired pulmonary function as a risk factor for mortality. Am J Epidemiol 1982; 116: 102-13.
4. Bang KM, Gergen PJ, Kramer R, Cohen B. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest 1993; 103: 536-40.
5. Cook DG, Shaper AG. Breathlessness, lung function and the risk of heart attack. Eur Heart J 1988; 9: 1215-22.
6. Ebi-Kryston KL. Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the Whitehall Study. J Clin Epidemiol 1988; 41: 251-60.
7. Lange P, Nyboe J, Jensen G, Schnohr P, Appleyard M. Ventilatory function impairment and risk of cardiovascular death and of fatal or non-fatal myocardial infarction. Eur Respir J 1991; 4: 1080-7.
8. Tockman MS, Comstock GW. Respiratory risk factors and mortality: longitudinal studies in Washington County, Maryland. Am Rev Respir Dis 1989; 140: S56-63.
9. Strachan DP. Ventilatory function as a predictor of fatal stroke. BMJ 1991; 302: 84-7.
10. Rodriguez BL, Masaki K, Burchfiel C et al. Pulmonary function decline and 17-year total mortality: the Honolulu Heart Program. Am J Epidemiol 1994; 140: 398-408.
11. Cullen K, Stenhouse NS, Wearne KL, Welborn TA. Multiple regression analysis of risk factors for cardiovascular disease and cancer mortality in Busselton, Western Australia-13-year study. J Chronic Dis 1983; 36: 371-7.
12. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996; 313: 711-5.
13. James AL, Knuiman MW, Divitini ML, Musk AW, Ryan G, Bartholomew HC. Associations between white blood cell count, lung function, respiratory illness and mortality: the Busselton Health Study. Eur Respir J 1999; 13: 1115-9.
14. Stavem K, Aaser E, Sandvik L et al. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. Eur Respir J 2005; 25: 618-25.
15. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996; 348: 567-72.
16. Rosengren A, Wilhelmsen L. Respiratory symptoms and long-term risk of death from cardiovascular disease, cancer and other causes in Swedish men. Int J Epidemiol 1998; 27: 962-9.
17. Huhti E, Ikkala J, Hakulinen T. Chronic respiratory disease, smoking and prognosis for life. An epidemiological study. Scand J Respir Dis 1977; 58: 170-80.
18. Carpenter L, Beral V, Strachan D, Ebi-Kryston KL, Inskip H. Respiratory symptoms as predictors of 27 years mortality in a representative sample of British adults. BMJ 1989; 299: 357-61.
19. Todd GF, Hunt BM, Lambert PM. Four cardiorespiratory symptoms as predictors of mortality. J Epidemiol Community Health 1978; 32: 267-74.
20. Peto R, Speizer FE, Cochrane AL et al. The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis 1983; 128: 491-500.
21. Ferris BGJ, Speizer FE, Worcester J, Chen HY. Adult mortality in Berlin, NH, from 1961 to 1967. Arch Environ Health 1971; 23: 434-9.
22. Friedman GD, Petitti DB, Bawol RD, Siegelaub AB. Mortality in cigarette smokers and quitters. Effect of base-line differences. N Engl J Med 1981; 304: 1407-10.
23. Sorlie PD, Kannel WB, O'Connor G. Mortality associated with respiratory function and symptoms in advanced age. The Framingham Study. Am Rev Respir Dis 1989; 140: 379-84.
24. Menotti A, Keys A, Kromhout D et al. All cause mortality and its determinants in middle aged men in Finland, The Netherlands, and Italy in a 25 years follow up. J Epidemiol Community Health 1991; 45: 125-30.
25. Olofson J, Skoogh BE, Bake B, Svardsudd K. Mortality related to smoking habits, respiratory symptoms and lung function. Eur J Respir Dis 1987; 71: 69-76.
26. Annesi I, Kauffmann F. Is respiratory mucus hypersecretion really an innocent disorder? A 22-year mortality survey of 1061 working men. Am Rev Respir Dis 1986; 134: 688-93.
27. Ebi-Kryston KL, Hawthorne VM, Rose G et al. Breathlessness, chronic bronchitis and reduced pulmonary function as predictors of cardiovascular disease mortality among men in England, Scotland and the United States. Int J Epidemiol 1989; 18: 84-8.
28. Wiles FJ, Hnizdo E. Relevance of airflow obstruction and mucus hypersecretion to mortality. Respir Med 1991; 85: 27-35.
29. Vestbo J, Knudsen KM, Rasmussen FV. Should we continue using questionnaires on breathlessness in epidemiologic surveys? Am Rev Respir Dis 1988; 137: 1114-8.
30. Blair SN, Kohl HW3, Paffenbarger RSJ, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 1989; 262: 2395-401.
31. Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N Engl J Med 1993; 328: 533-7.
32. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346: 793-801.
33. Lochen ML, Rasmussen K. The Tromso study: physical fitness, self reported physical activity, and their relationship to other coronary risk factors. J Epidemiol Community Health 1992; 46: 103-7.
34. Erikssen J, Enger SC. Smoking, lung function, physical performance and latent coronary heart disease in presumably healthy middle-aged men. Acta Med Scand 1978; 203: 509-16.
35. Rose GA, Blackburn H. Cardiovascular Survey Methods. Geneva: World Health Organization, 1968.
36. Quanjer PH, Tammeling GJ. Summary of recommendations. Bull Eur Physiopathol Respir 1983; 19 (Suppl. 5): 7-10.
37. Gulsvik A, Tosteson T, Bakke P, Humerfelt S, Weiss ST, Speizer FE. Expiratory and inspiratory forced vital capacity and one-second forced volume in asymptomatic never-smokers in Norway. Clin Physiol 2001; 21: 648-60.
38. Medical Research Council's Committee on the Aetiology of Chronic Bronchitis. Standardised questionnaire on respiratory symptoms. Br Med J (Clin Res) 1960; 2: 1665.
39. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972; 34: 187-220.
40. Blair SN, Kampert JB, Kohl HW3 et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA 1996; 276: 205-10.
41. Laukkanen JA, Lakka TA, Rauramaa R et al. Cardiovascular fitness as a predictor of mortality in men. Arch Intern Med 2001; 161: 825-31.
42. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrics 1994; 81: 515-26.
43. Knuiman MW, James AL, Divitini ML, Ryan G, Bartholomew HC, Musk AW. Lung function, respiratory symptoms, and mortality: results from the Busselton Health Study. Ann Epidemiol 1999; 9: 297-306.
44. Schroeder EB, Welch VL, Couper D et al. Lung function and incident coronary heart disease: the atherosclerosis risk in communities study. Am J Epidemiol 2003; 158: 1171-81.
45. Vestbo J. Epidemiological studies in mucus hypersecretion. Novartis Found Symp 2002; 248: 3-12.
46. Persson C, Bengtsson C, Lapidus L, Rybo E, Thiringer G, Wedel H. Peak expiratory flow and risk of cardiovascular disease and death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Am J Epidemiol 1986; 124: 942-8.
47. Cook NR, Evans DA, Scherr PA, Speizer FE, Taylor JO, Hennekens CH. Peak expiratory flow rate and 5-year mortality in an elderly population. Am J Epidemiol 1991; 133: 784-94.
48. Talbot LA, Morrell CH, Metter EJ, Fleg JL. Comparison of cardiorespiratory fitness versus leisure time physical activity as predictors of coronary events in men aged ≤65 years and >65 years. Am J Cardiol 2002; 89: 1187-92.
49. Kaplan GA, Kotler PL. Self-reports predictive of mortality from ischemic heart disease: a nine-year follow-up of the Human Population Laboratory cohort. J Chronic Dis 1985; 38: 195-201.
50. Vestbo J, Knudsen KM, Rasmussen FV. Are respiratory symptoms and chronic airflow limitation really associated with an increased risk of respiratory cancer? Int J Epidemiol 1991; 20: 375-8.
51. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Ventilatory function and chronic mucus hypersecretion as predictors of death from lung cancer. Am Rev Respir Dis 1990; 141: 613-7.
52. Dockerty JD. Outpatient clinic nonarrivals and cancellations. N Z Med J 1992; 105: 147-9.
53. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 1990; 45: 579-85.
54. Zeiner-Henriksen T. Six year mortality related to cardiorespiratory symptoms and environmental risk factors in a sample of the Norwegian population. J Chronic Dis 1976; 29: 15-33.
55. Higgins M, Keller JB, Wagenknecht LE et al. Pulmonary function and cardiovascular risk factor relationships in black and in white young men and women. The CARDIA Study. Chest 1991; 99: 315-22.
56. Samet JM. A historical and epidemiologic perspective on respiratory symptoms questionnaires. Am J Epidemiol 1978; 108: 435-46.
57. Blane D, Hart CL, Smith GD, Gillis CR, Hole DJ, Hawthorne VM. Association of cardiovascular disease risk factors with socioeconomic position during childhood and during adulthood. BMJ 1996; 313: 1434-8.
58. Smith GD, Hart C, Watt G, Hole D, Hawthorne V. Individual social class, area-based deprivation, cardiovascular disease risk factors, and mortality: the Renfrew and Paisley Study. J Epidemiol Community Health 1998; 52: 399-405.
59. Shohaimi S, Welch A, Bingham S et al. Area deprivation predicts lung function independently of education and social class. Eur Respir J 2004; 24: 157-61.
60. Leffondre K, Abrahamowicz M, Siemiatycki J, Rachet B. Modeling smoking history: a comparison of different approaches. Am J Epidemiol 2002; 156: 813-23.